SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

02 8 2022 06:00:01 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

15 7 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day

10 6 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

09 6 2022 06:00:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

26 5 2022 16:15:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors

24 5 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022

16 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 5 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma

19 4 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

24 2 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

01 2 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 1 2022 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

10 12 2021 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

06 12 2021 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

29 11 2021 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

23 11 2021 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

04 11 2021 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma

27 10 2021 05:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

20 10 2021 05:45:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

20 10 2021 05:30:00 提供 Nasdaq GlobeNewswire